The GLP-1 obesity drug market is considered a long-term, durable investment category. The competitive landscape is highlighted by Eli Lilly's strong execution versus Novo Nordisk's efforts, with the recent approval of Novo's oral pill not seen as enough to shift the balance.
There is a strong expectation for increased M&A activity driven by large pharmaceutical companies needing to fill holes in their drug pipelines. The scarcity of high-quality assets makes smaller biotechs with positive clinical data prime acquisition targets.
The discussion on Merck & Co. exemplifies the strategic challenge of managing the loss of exclusivity (LOE) for blockbuster drugs like Keytruda. The company is being rewarded by the market for successfully developing and acquiring new assets to ensure growth beyond its key patent expiration.
The analyst expresses concern over disorganization and a lack of clarity at the U.S. Food and Drug Administration (FDA). This uncertainty is presented as a drag on the sector, and increased regulatory clarity is viewed as a potential catalyst for improved performance, especially for smaller biotech companies.
Keep pulling the thread on Evan Seigerman.